Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma

Table 5 Inter- and intra-reader performance results

Study outline	Design	Inter-reader, % (95 % CI)	Intra-reader, % (95 % CI)
NSCLC cases: inter- and intra-reader agreement on a cohort previously screened for PD-L1 status	81 cases 40 PD-L1 high 41 PD-L1 low/negative	APA 96.6 % (93.8–98.8) ANA 96.8 % (93.9–98.9) OPA 96.7 % (94.2–98.9)	APA 96.2 % (92.7–98.8) ANA 96.4 % (93.0–98.8) OPA 96.3 % (93.3–98.8)
HNSCC cases: inter- and intra- reader agreement on a cohort previously screened for PD-L1 status	100 cases 50 PD-L1 high 50 PD-L1 low/negative	APA 90.9 % (86.0–94.9) ANA 90.8 % (86.0–94.8) OPA 90.8 % (86.7–94.7)	APA 94.4 % (91.1–97.1) ANA 94.3 % (91.0–97.1) OPA 94.3 % (91.3–97.0)

ANA average negative agreement, APA average positive agreement, CI confidence interval, HNSCC head and neck squamous cell carcinoma, NSCLC non-small cell lung cancer, OPA overall percentage agreement, PD-L1 programmed cell death ligand-1

ISSN: 1746-1596